Answers are grounded in this paper and cite their sources.
Demonstrates enhanced classification of cancer subtypes in multiomics data, suggesting improved interpretability and accuracy.
Integrating multiomics data for cancer subtype classification remains a critical yet challenging task due to the high dimensionality, heterogeneity, and limited interpretability of omics features. To address these limitations, we propose OmniCLIC, a unified Omics Contrastive Learning and Integration Classification framework that enables end-to-end multiomics integration, feature learning, and prediction. Three key components are proposed in OmniCLIC: OmniNet, a customized MLP with feature-wise scaling, neural tangent parametrization, and regularization strategies for omics-specific representation learning; a contrastive learning module that jointly optimizes supervised contrastive and cross-entropy losses; and OCDN, a decision-level fusion module that captures interomics correlations via a cross-modal correlation tensor to enhance generalization. We evaluate OmniCLIC on four benchmark cancer data sets, where it consistently outperforms state-of-the-art methods in accuracy and robustness across both binary and multiclass multiomics data sets. Furthermore, OmniCLIC enables biologically meaningful interpretation by identifying key molecular features through its built-in scaling layers. Functional enrichment analyses on the selected features reveal subtype-specific pathways, such as epithelial morphogenesis and PI3K-Akt signaling, aligned with known cancer biology. We further extend OmniCLIC to single-cell multiomics data (RNA+ATAC, RNA+ADT), where it still outperforms existing methods, verifying the framework's generalizability across multiomics data at different scales.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: